We found that metformin decreased the TLR4 level and pro-inflammatory response in all NAFLD patients; however, its efficacy depended on their health and phenotype status at the beginning of the study, in particular the presence of obesity. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.